Sonnet BioTherapeutics I... (SONN)
NASDAQ: SONN
· Real-Time Price · USD
3.40
-0.36 (-9.57%)
At close: Aug 15, 2025, 10:09 AM
-9.57% (1D)
| Bid | 2.71 |
| Market Cap | 21.27M |
| Revenue (ttm) | 1M |
| Net Income (ttm) | -13.29M |
| EPS (ttm) | -6.82 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | -0.03 |
| Analyst | Buy |
| Ask | 4.36 |
| Volume | 240,146 |
| Avg. Volume (20D) | 3,998,445 |
| Open | 3.68 |
| Previous Close | 3.76 |
| Day's Range | 3.38 - 3.75 |
| 52-Week Range | 1.08 - 19.30 |
| Beta | 1.05 |
About SONN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SONN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SONN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+86.46%
Sonnet BioTherapeutics shares are trading higher a...
Unlock content with
Pro Subscription
8 months ago
-5.71%
Sonnet BioTherapeutics shares are trading higher after the company announced the highest dose of its Phase 1 SB101 trial results for SON-1010 have been formally evaluated by the safety review committee, with the maximum tolerated dose set at 1200ng/kg.
